Compass Pathways Osake

Compass Pathways EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Compass Pathways (CMPS) 17.7.2026 päivämäärällä on −178,21 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −127,12 M USD — muutos 40,19 % (matalampi).

EBITDA

−178,21 MUSD

YoY

40,19%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Compass Pathways on 2026 −178,21 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Compass Pathways oli 2025 −127,12 M USD. Se laskee 40,19% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Compass Pathways Osakeanalyysi

Mitä Compass Pathways tekee? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Compass Pathways osakkeesta

Yhtiön Compass Pathways EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −178,21 M USD vuonna 2026.

Access this data via the Eulerpool API

Tuloslaskelma — Compass Pathways

Kaikki tunnusluvut — Compass Pathways